Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
The report details the trend, potential and market size of Peptide Based Metabolic Disorders Therapeutics market, and analyzes the current situation and prospects of the market from both qualitative and quantitative aspects, which can be roughly divided into three parts.
The first part (Chapter1-7) mainly covers the qualitative analysis of Peptide Based Metabolic Disorders Therapeuticsmarket, defines the market attractiveness level of Peptide Based Metabolic Disorders Therapeutics market through Porter's Five Forces Analysis, and summarizes the different factors in the overall environment through PEST analysis. Understand the distribution of industrial chain value in each link of industrial chain through the analysis of industrial chain structure. Thus estimate the market space of each link.
The second part (Chapter8-12), based on the segmentation of Peptide Based Metabolic Disorders Therapeutics industry, describes the types of Peptide Based Metabolic Disorders Therapeutics market, the applications of major players and the market size, and deeply analyzes the current situation of the global Peptide Based Metabolic Disorders Therapeutics market and the development prospects and opportunities of Peptide Based Metabolic Disorders Therapeutics industry.
The third part (Chapter14-15) includes the market positions of the major players and information on the market participants, which will help you gain a comprehensive understanding of the current competitive situation and potential growth opportunities in the market.
As COVID-19 continues to impact the global economy in 2022, the report also considers the short - and long-term impacts of COVID-19 on the global Peptide Based Metabolic Disorders Therapeutics market in Chapter 13.
By Player:
Eli Lilly
Teva Pharmaceutical
Ipsen
Novo Nordisk
Merck
AstraZeneca
Ingro Finanz (Bachem)
PolyPeptide Group
By Type:
Exenatide
Liraglutide
Others
By End-User:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Geography:
-
United States
-
Europe
-
China
-
Japan
-
India
-
South Korea
TABLE OF CONTENT
1 Introduction
-
1.1 Market Definition
-
1.2 Market Segment Analysis
-
1.3 Market Size 2022
-
1.4 Peptide Based Metabolic Disorders Therapeutics Market Outlook: Forecast for 2022 - 2028
-
1.5 Pricing Analysis
2 Executive Summary
3 Peptide Based Metabolic Disorders Therapeutics Market Lineage Outlook
-
3.1 Parent Market Outlook
-
3.2 Related/Ancillary Market Outlook
-
3.3 Penetration & Growth Prospect Mapping, 2022
4 Market Analysis Tools: Porter's Five Forces
-
4.1 Supplier Power
-
4.2 Buyer Power
-
4.3 Substitution Threat
-
4.4 Threat of New Entrants
-
4.5 Competitive Rivalry
5 Peptide Based Metabolic Disorders Therapeutics Industry Analysis - PEST (Political & Legal, Economic, Social, and Technological)
-
5.1 Political/Legal Landscape
-
5.2 Economic Landscape
-
5.3 Social Landscape
-
5.4 Technology Landscape
6 Peptide Based Metabolic Disorders Therapeutics Market - Value Chain Analysis
-
6.1 Industry's Value Chain Analysis
-
6.2 Product Life Cycle
-
6.3 User Perspective Analysis
7 Region and Country-wise Peptide Based Metabolic Disorders Therapeutics Market Analysis and Outlook to 2022
-
7.1 Global Peptide Based Metabolic Disorders Therapeutics Consumption (2017-2022)
-
7.2 United States Peptide Based Metabolic Disorders Therapeutics Consumption (2017-2022)
-
7.3 Europe Peptide Based Metabolic Disorders Therapeutics Consumption (2017-2022)
-
7.4 China Peptide Based Metabolic Disorders Therapeutics Consumption (2017-2022)
-
7.5 Japan Peptide Based Metabolic Disorders Therapeutics Consumption (2017-2022)
-
7.6 India Peptide Based Metabolic Disorders Therapeutics Consumption (2017-2022)
-
7.7 South Korea Peptide Based Metabolic Disorders Therapeutics Consumption (2017-2022)
8 Region and Country-wise Peptide Based Metabolic Disorders Therapeutics Market Analysis and Outlook to 2028
-
8.1 Global Peptide Based Metabolic Disorders Therapeutics Consumption Forecast (2022-2028)
-
8.2 United States Peptide Based Metabolic Disorders Therapeutics Consumption Forecast (2022-2028)
-
8.3 Europe Peptide Based Metabolic Disorders Therapeutics Consumption Forecast (2022-2028)
-
8.4 China Peptide Based Metabolic Disorders Therapeutics Consumption Forecast (2022-2028)
-
8.5 Japan Peptide Based Metabolic Disorders Therapeutics Consumption Forecast (2022-2028)
-
8.6 India Peptide Based Metabolic Disorders Therapeutics Consumption Forecast (2022-2028)
-
8.7 South Korea Peptide Based Metabolic Disorders Therapeutics Consumption Forecast (2022-2028)
9 Global Peptide Based Metabolic Disorders Therapeutics Market Outlook by Types and Applications to 2022
-
9.1 Global Peptide Based Metabolic Disorders Therapeutics Consumption and Growth Rate by Type (2017-2022)
-
9.1.1 Global Exenatide Consumption and Growth Rate (2017-2022)
-
9.1.2 Global Liraglutide Consumption and Growth Rate (2017-2022)
-
9.1.3 Global Others Consumption and Growth Rate (2017-2022)
-
9.2 Global Peptide Based Metabolic Disorders Therapeutics Consumption and Growth Rate by Application (2017-2022)
-
9.2.1 Global Hospital Pharmacies Consumption and Growth Rate (2017-2022)
-
9.2.2 Global Retail Pharmacies Consumption and Growth Rate (2017-2022)
-
9.2.3 Global Online Pharmacies Consumption and Growth Rate (2017-2022)
10 Global Peptide Based Metabolic Disorders Therapeutics Market Outlook by Types and Applications to 2028
-
10.1 Global Peptide Based Metabolic Disorders Therapeutics Consumption Forecast and Growth Rate by Type (2022-2028)
-
10.1.1 Global Exenatide Consumption Forecast and Growth Rate (2022-2028)
-
10.1.2 Global Liraglutide Consumption Forecast and Growth Rate (2022-2028)
-
10.1.3 Global Others Consumption Forecast and Growth Rate (2022-2028)
-
10.2 Global Peptide Based Metabolic Disorders Therapeutics Consumption Forecast and Growth Rate by Application (2022-2028)
-
10.2.1 Global Hospital Pharmacies Consumption Forecast and Growth Rate (2022-2028)
-
10.2.2 Global Retail Pharmacies Consumption Forecast and Growth Rate (2022-2028)
-
10.2.3 Global Online Pharmacies Consumption Forecast and Growth Rate (2022-2028)
11 Global Peptide Based Metabolic Disorders Therapeutics Import and Export Analysis (Top 5 Countries)
-
11.1 Global Peptide Based Metabolic Disorders Therapeutics Import by Region (Top 5 Countries) (2017-2028)
-
11.2 Global Peptide Based Metabolic Disorders Therapeutics Export by Region (Top 5 Countries) (2017-2028)
12 Coronavirus Disease (COVID-19) Impact
-
12.1 Industry Impact Analysis
-
12.2 Peptide Based Metabolic Disorders Therapeutics Market Outlook to 2028 - COVID-19 Affected Forecasts
13 Competition Matrix
-
13.1 Target Markets
-
13.2 Comprehensive Analysis of Products in Competitive Markets
14 Global Peptide Based Metabolic Disorders Therapeutics Market Competitive Analysis
-
14.1 Eli Lilly
-
14.1.1 Eli Lilly Company Details
-
14.1.2 Eli Lilly Peptide Based Metabolic Disorders Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
14.1.3 Eli Lilly Peptide Based Metabolic Disorders Therapeutics Product and Service
-
14.2 Teva Pharmaceutical
-
14.2.1 Teva Pharmaceutical Company Details
-
14.2.2 Teva Pharmaceutical Peptide Based Metabolic Disorders Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
14.2.3 Teva Pharmaceutical Peptide Based Metabolic Disorders Therapeutics Product and Service
-
14.3 Ipsen
-
14.3.1 Ipsen Company Details
-
14.3.2 Ipsen Peptide Based Metabolic Disorders Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
14.3.3 Ipsen Peptide Based Metabolic Disorders Therapeutics Product and Service
-
14.4 Novo Nordisk
-
14.4.1 Novo Nordisk Company Details
-
14.4.2 Novo Nordisk Peptide Based Metabolic Disorders Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
14.4.3 Novo Nordisk Peptide Based Metabolic Disorders Therapeutics Product and Service
-
14.5 Merck
-
14.5.1 Merck Company Details
-
14.5.2 Merck Peptide Based Metabolic Disorders Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
14.5.3 Merck Peptide Based Metabolic Disorders Therapeutics Product and Service
-
14.6 AstraZeneca
-
14.6.1 AstraZeneca Company Details
-
14.6.2 AstraZeneca Peptide Based Metabolic Disorders Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
14.6.3 AstraZeneca Peptide Based Metabolic Disorders Therapeutics Product and Service
-
14.7 Ingro Finanz (Bachem)
-
14.7.1 Ingro Finanz (Bachem) Company Details
-
14.7.2 Ingro Finanz (Bachem) Peptide Based Metabolic Disorders Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
14.7.3 Ingro Finanz (Bachem) Peptide Based Metabolic Disorders Therapeutics Product and Service
-
14.8 PolyPeptide Group
-
14.8.1 PolyPeptide Group Company Details
-
14.8.2 PolyPeptide Group Peptide Based Metabolic Disorders Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
14.8.3 PolyPeptide Group Peptide Based Metabolic Disorders Therapeutics Product and Service
15 Appendix
TABLE OF CHARTS
-
Table Definition of Peptide Based Metabolic Disorders Therapeutics
-
Figure Peptide Based Metabolic Disorders Therapeutics Picture
-
Table Global Peptide Based Metabolic Disorders Therapeutics Market Size and Forecast 2022 - 2028 (USD million)
-
Figure Global Peptide Based Metabolic Disorders Therapeutics Market Size and Forecast 2022 - 2028 (USD million)
-
Figure Global Peptide Based Metabolic Disorders Therapeutics Market: Year-over-year Growth 2022 - 2028 (%)
-
Table Parent Market Analysis
-
Figure Parent Market Price
-
Table Related/Ancillary Market Outlook Analysis
-
Table Supplier Power Analysis
-
Table Buyer Power Analysis
-
Table Substitution Threat Analysis
-
Table Threat of New Entrants Analysis
-
Table Competitive Rivalry Analysis
-
Figure Global Peptide Based Metabolic Disorders Therapeutics Consumption by Country (2017-2022)
-
Figure United States Peptide Based Metabolic Disorders Therapeutics Consumption and Growth Rate (2017-2022)
-
Table Europe Peptide Based Metabolic Disorders Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure China Peptide Based Metabolic Disorders Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Japan Peptide Based Metabolic Disorders Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure India Peptide Based Metabolic Disorders Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure South Korea Peptide Based Metabolic Disorders Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Global Peptide Based Metabolic Disorders Therapeutics Consumption Forecast by Country (2022-2028)
-
Figure United States Peptide Based Metabolic Disorders Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Table Europe Peptide Based Metabolic Disorders Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure China Peptide Based Metabolic Disorders Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Japan Peptide Based Metabolic Disorders Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure India Peptide Based Metabolic Disorders Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Korea Peptide Based Metabolic Disorders Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Exenatide Consumption and Growth Rate (2017-2022)
-
Figure Global Liraglutide Consumption and Growth Rate (2017-2022)
-
Figure Global Others Consumption and Growth Rate (2017-2022)
-
Figure Global Hospital Pharmacies Consumption and Growth Rate (2017-2022)
-
Figure Global Retail Pharmacies Consumption and Growth Rate (2017-2022)
-
Figure Global Online Pharmacies Consumption and Growth Rate (2017-2022)
-
Figure Global Exenatide Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Liraglutide Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Others Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Hospital Pharmacies Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Retail Pharmacies Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Online Pharmacies Consumption Forecast and Growth Rate (2022-2028)
-
Table Global Peptide Based Metabolic Disorders Therapeutics Import by Region (Top 5 Countries) (2017-2028)
-
Table Global Peptide Based Metabolic Disorders Therapeutics Export by Region (Top 5 Countries) (2017-2028)
-
Table Eli Lilly (Foundation Year, Company Profile and etc.)
-
Table Eli Lilly Peptide Based Metabolic Disorders Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
Table Eli Lilly Peptide Based Metabolic Disorders Therapeutics Product and Service
-
Table Teva Pharmaceutical (Foundation Year, Company Profile and etc.)
-
Table Teva Pharmaceutical Peptide Based Metabolic Disorders Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
Table Teva Pharmaceutical Peptide Based Metabolic Disorders Therapeutics Product and Service
-
Table Ipsen (Foundation Year, Company Profile and etc.)
-
Table Ipsen Peptide Based Metabolic Disorders Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
Table Ipsen Peptide Based Metabolic Disorders Therapeutics Product and Service
-
Table Novo Nordisk (Foundation Year, Company Profile and etc.)
-
Table Novo Nordisk Peptide Based Metabolic Disorders Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
Table Novo Nordisk Peptide Based Metabolic Disorders Therapeutics Product and Service
-
Table Merck (Foundation Year, Company Profile and etc.)
-
Table Merck Peptide Based Metabolic Disorders Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
Table Merck Peptide Based Metabolic Disorders Therapeutics Product and Service
-
Table AstraZeneca (Foundation Year, Company Profile and etc.)
-
Table AstraZeneca Peptide Based Metabolic Disorders Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
Table AstraZeneca Peptide Based Metabolic Disorders Therapeutics Product and Service
-
Table Ingro Finanz (Bachem) (Foundation Year, Company Profile and etc.)
-
Table Ingro Finanz (Bachem) Peptide Based Metabolic Disorders Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
Table Ingro Finanz (Bachem) Peptide Based Metabolic Disorders Therapeutics Product and Service
-
Table PolyPeptide Group (Foundation Year, Company Profile and etc.)
-
Table PolyPeptide Group Peptide Based Metabolic Disorders Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
Table PolyPeptide Group Peptide Based Metabolic Disorders Therapeutics Product and Service
-
